IQVIA Holdings Inc. $IQV Shares Acquired by Andra AP fonden

Andra AP fonden increased its position in shares of IQVIA Holdings Inc. (NYSE:IQV) by 320.1% during the 1st quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 121,405 shares of the medical research company’s stock after purchasing an additional 92,505 shares during the period. Andra AP fonden’s holdings in IQVIA were worth $20,704,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Ameliora Wealth Management Ltd. acquired a new position in shares of IQVIA during the 4th quarter valued at $25,000. Financial Freedom LLC acquired a new stake in shares of IQVIA in the first quarter valued at $25,000. Ascentis Independent Advisors bought a new position in IQVIA during the first quarter valued at about $25,000. International Assets Investment Management LLC acquired a new position in IQVIA during the fourth quarter worth about $27,000. Finally, Gilpin Wealth Management LLC bought a new stake in IQVIA in the fourth quarter worth about $27,000. 89.62% of the stock is owned by institutional investors.

Wall Street Analyst Weigh In

IQV has been the subject of several research reports. Robert W. Baird raised their price objective on shares of IQVIA from $230.00 to $249.00 and gave the company an “outperform” rating in a research report on Wednesday, July 1st. Wall Street Zen downgraded shares of IQVIA from a “buy” rating to a “hold” rating in a report on Saturday, June 27th. Weiss Ratings raised shares of IQVIA from a “hold (c-)” rating to a “hold (c)” rating in a research note on Wednesday, July 15th. Deutsche Bank Aktiengesellschaft set a $240.00 price target on shares of IQVIA in a research report on Thursday, July 9th. Finally, Evercore reaffirmed an “outperform” rating and issued a $185.00 price target on shares of IQVIA in a report on Wednesday, April 8th. Fourteen equities research analysts have rated the stock with a Buy rating and three have issued a Hold rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average target price of $225.71.

IQVIA Stock Performance

IQVIA stock opened at $204.33 on Tuesday. IQVIA Holdings Inc. has a fifty-two week low of $154.50 and a fifty-two week high of $247.04. The firm’s 50 day simple moving average is $185.66 and its 200-day simple moving average is $187.72. The company has a debt-to-equity ratio of 2.20, a current ratio of 0.75 and a quick ratio of 0.75. The company has a market cap of $34.10 billion, a P/E ratio of 25.32, a price-to-earnings-growth ratio of 1.85 and a beta of 1.20.

IQVIA (NYSE:IQV) last issued its quarterly earnings results on Tuesday, May 5th. The medical research company reported $2.90 EPS for the quarter, beating the consensus estimate of $2.83 by $0.07. IQVIA had a net margin of 8.33% and a return on equity of 30.50%. The business had revenue of $4.15 billion during the quarter, compared to the consensus estimate of $4.10 billion. During the same quarter in the prior year, the firm earned $2.70 EPS. The firm’s quarterly revenue was up 8.4% on a year-over-year basis. IQVIA has set its FY 2026 guidance at 12.650-12.950 EPS. As a group, equities research analysts predict that IQVIA Holdings Inc. will post 11.57 EPS for the current year.

IQVIA declared that its board has authorized a stock repurchase plan on Thursday, May 7th that allows the company to buyback $2.00 billion in outstanding shares. This buyback authorization allows the medical research company to purchase up to 6.8% of its shares through open market purchases. Shares buyback plans are typically a sign that the company’s management believes its shares are undervalued.

About IQVIA

IQVIA (NYSE: IQV) is a global provider of advanced analytics, technology solutions and contract research services to the life sciences industry. The company combines clinical research capabilities with large-scale health data and analytics to support drug development, regulatory reporting, commercial strategy and real‑world evidence generation. IQVIA traces its current form to the combination of Quintiles and IMS Health announced in 2016 and subsequently rebranded as IQVIA, bringing together long-established clinical research operations and extensive healthcare information assets.

IQVIA’s principal activities include outsourced clinical development services (acting as a contract research organization for phases I–IV), real‑world evidence and observational research, regulatory and safety services, and a suite of technology platforms that enable data integration, analytics and operational management.